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It is important to stage ﬁbrosis in chronic hepatitis for 2 pur-
poses: to select candidates for therapy and to follow ﬁbrosis pro-
gression/regression on treatment. Chronic viral hepatitis is a
prolonged inﬂammatory disease of the liver that may lead to
the progressive development of ﬁbrosis. Because ﬁbrosis and its
end-point cirrhosis are the main causes of morbidity and mortal-
ity, ﬁbrosis assessment is considered as the most relevant infor-
mation for the evaluation of the severity of the disease and as a
useful indicator for prognosis and treatment decision. Because
ﬁbrosis is a morphological damage, liver biopsy has come to be
the natural gold standard for staging the disease. However, the
high prevalence of chronic hepatitis B in addition to the morbid-
ity and the cost generated by this procedure have triggered an
intensive search for alternative methods for ﬁbrosis evaluation.
A number of non-invasive techniques have been developed which
can be used instead of liver biopsy to assess liver disease severity,
including serum markers and transient elastography [1,2]. How-
ever, most non-invasive tests fail to differentiate between adja-
cent stages of ﬁbrosis, and are generally only accurate when
distinguishing cirrhosis from no or minimal ﬁbrosis [3]. There-
fore, despite sampling error, liver biopsy remains the gold stan-
dard for determining histologic grade and stage. Speciﬁcally, in
HBV infection, patients for whom antiviral therapy is being con-
sidered, are candidates for liver biopsy to assess ﬁbrosis stage.
Indeed, clinical guidelines on the management of chronic HBV
infection recommend liver biopsy as the reference method for
evaluation of liver disease for both diagnosis and assessment of
eligibility for treatment [4]. Furthermore, it has been demon-
strated that regression of ﬁbrosis is usually obtained with main-
tained on-treatment HBV inhibition during long-term therapy
with nucleos(t)ide analogues such as entecavir or tenofovirJournal of Hepatology 20
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pen access under CC BY-NC-ND license.[5–7]. Also, there is now strong evidence that not only ﬁbrosis
but also cirrhosis can also be reversed in a signiﬁcant proportion
of patients when HBV replication is controlled. Since cirrhosis rever-
sion may change prognosis and signiﬁcantly reduce the risk of end-
stage liver disease-related complications, it might be clinically rele-
vant to look for cirrhosis reversal after long-term HBV oral therapy.How to assess ﬁbrosis?
Semiquantitative scoring systems are part of histological assess-
ment (METAVIR, Knodell, Ishak score) (Table 1) [8,9]. Fibrosis is
scored in stages while necroinﬂammation is evaluated by grade.
Staging ﬁbrosis is an assessment of the combination of the
amount of ﬁbrosis and architectural disorganization. These semi-
quantitative histological scores are used in both clinical trials and
for individual evaluation.
A more quantitative approach for ﬁbrosis assessment is mor-
phometry, a technique based on image analysis of digitalized tis-
sue sections. Liver sections had to be stained with sirius red, a
stain that binds to all connective tissue, but primarily to collagen
as proven by a correlation between the amount of bound stain
and the chemically determined collagen content [10]. The quan-
tiﬁcation of total ﬁbrosis is usually expressed as a percentage, the
ratio of ﬁbrous tissue area stained with sirius red upon the total
tissue surface (Collagen Proportional area or CPA). Fibrosis pro-
gression (or regression) can be deﬁned as any increase (or reduc-
tion) in ﬁbrosis amount when comparing paired liver biopsies.What have we learned from qFibrosis?
In this issue of Journal of Hepatology, Xu et al. developed qFibro-
sis: a fully-automated method incorporating both collagen
amount quantitation and information about spatial location and
organisation of ﬁbrous tissue through a sophisticated automated
process with the use of a proprietary algorithm. This approach
was tested in an animal model of ﬁbrosis and liver biopsies of
chronic hepatitis B patients [11]. The main ﬁbrosis patterns,
namely, portal collagen (portal expansion), septal collagen
(bridging ﬁbrosis), and ﬁbrillar collagen (ﬁne collagen distributed
in the pericellular/perisinusoidal space of Disse) were identiﬁed14 vol. 61 j 193–195
Table 1. Liver biopsy in viral hepatitis – scoring systems in liver ﬁbrosis.
Fibrosis staging METAVIR
No fibrosis No fibrosis No fibrosis




1 Fibrosis portal 
expansion
1 Some portal tract fibrotic ± short fibrous
septa
septa








Cirrhosis 4 Cirrhosis 4 Marked P-P and/or P-C bridging 






Most portal tract fibrotic with occasional
P-P bridging
Septal fibrosis Portal tract fibrotic with marked P-P and
P-C bridging
Cirrhosis (probable or definite)
P-P, portal to portal; P-C, portal to central.
Editorialthrough image acquisition and processing, and translated into
quantitative parameters to build up qFibrosis indices.
qFibrosis relies on a special microscope imaging technique
that allows efﬁcient collection of ﬁbrous architectural informa-
tion, the non-linear optical second harmonic generation (SHG)/
two-photon excitation ﬂuorescence (TPEF) microscopy that was
previously reported [12,13]. SHG/TPEF can analyse and quantify
collagen ﬁbers in 2D and 3D formats because of the intrinsic194 Journal of Hepatology 201optical properties of ﬁbrillar collagen molecules in stain-free
biopsy sections [14].
In the rat model, qFibrosis values increased with ﬁbrosis pro-
gression and showed signiﬁcant differences between all semi-
quantitative stages of ﬁbrosis (p <0.001) while CPA showed
drastic changes only in advanced stages ﬁbrosis and was unable
to differentiate between early stages. In the chronic hepatitis B
biopsies, qFibrosis values, obtained from 69 biopsies longer than4 vol. 61 j 193–195
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15 mm, successfully differentiated between all METAVIR stages
(p <0.05). In comparison, CPA could only differentiate between
stages 3 and 4.
The authors reported that qFibrosis was less sensitive to sam-
pling error. Also qFibrosis can aid in correction of sampling error-
mediated intraobserver variation.
In an independent cohort of chronic hepatitis B liver biopsies,
qFibrosis indices faithfully replicated Metavir ﬁbrosis scoring,
with better differentiation ability between stages than with CPA
measurements. The AUC values of qFibrosis for detection of dif-
ferent stages were from 0.90 to 0.95, while the AUC values of
CPA were smaller (0.84–0.92).
Thus, this piece of work demonstrates the accuracy and repro-
ducibility of qFibrosis as a new parameter in quantitative evalu-
ation of liver ﬁbrosis. Nevertheless, and before claiming its wide
diffusion, this needs further studies. First, it remains to demon-
strate the additional value of this sophisticated technique which
is costly and time-consuming by comparison to the usual semi-
quantitative scoring systems. Although semiquantitative scores
have been proved to be clinically relevant, the clinical relevance
in assessment of such a level of accuracy needs to be demon-
strated. To date, and despite signiﬁcant technical development
in the past 30 years, the place of quantitative image analysis of
liver ﬁbrosis is still limited. CPA is used only in evaluation of
ﬁbrosis in clinical trials although a recent study suggest this
approach might be relevant for prognosis. Furthermore, the pat-
tern of ﬁbrosis changes according to etiology of the underlying
chronic liver disease. Indeed, while in viral hepatitis ﬁbrosis
spread from periportal area, ﬁbrosis is mainly perisinusoidal
and located in zone 3 in NAFLDs. Since qFibrosis includes pattern
of ﬁbrosis into the quantiﬁcation algorithm, there is strong sup-
position that one algorithm will not ﬁt for all diseases. And what
about associated comorbidities such as hepatitis C and NAFLD?
Although there is an urgent need to validate new non-invasive
markers, qFibrosis will still need to sample the liver.
Finally, this study convincingly demonstrates the accuracy
and reproducibility of qFibrosis as a new tool in quantitative eval-
uation of liver ﬁbrosis. This innovative approach has still to ﬁnd
its way but it may enhance the information provided by the liver
biopsy especially in the context of clinical research in chronic
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